Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > ebr > summer 2003 > maximising return on investment with r&d portfolio management

PUBLICATIONS

European BioPharmaceutical Review Maximising Return on Investment with R&D Portfolio Management
Product prioritisation at a tactical level - identifying the most desirable and attractive products in a company's R&D pipeline - remains the primary focus of portfolio management today. This factor, coupled with the need to maximise return on investment, acts as a strong driving force for pharmaceutical companies to perform portfolio management.
Read full article >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

By Morten Soegaard, Research Analyst at Frost & Sullivan

Morten Soegaard, a Research Analyst at Frost & Sullivan, has recently finished his analysis on R&D Portfolio Management. As a member of the pharmaceuticals team he previously investigated the European market on commercial opportunities for inhalation drug delivery in diabetes.